WuXi's Customer Focused Business Model Shows the Changing Relationship Between Drug Makers and CROs
Executive Summary
Beset by the hurdlesand dynamics of drug discovery, service providers have evolved from traditional vendors performing non-core support to their pharma and biotech customers, to becoming critical partners. WuXi has adapted quickly to seize new opportunities.
You may also be interested in...
China: The Asian Dragon Lures Foreign Investors
WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.